DVM

Seriate, Italy
Seriate, Italy
SEARCH FILTERS
Time filter
Source Type

News Article | May 12, 2017
Site: globenewswire.com

OTTAWA, Ontario, May 12, 2017 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV) (OTC Pink:CHEXF) (Avivagen or the Corporation), a Corporation with a proven and commercially-ready, patent-protected product intended to replace the antibiotics added to livestock feeds as growth promoters, announces the hiring of a regulatory consulting firm to work with the Corporation to analyze and seek regulatory approvals of Avivagen’s OxC-beta™ for Livestock in the United States. Avivagen has already secured approvals in several Asian markets and will be seeking to confirm the regulatory pathway for approvals in the U.S., Europe, South America and other important markets. Avivagen believes that obtaining  regulatory approval in additional jurisdictions could  increase the market access of OxC-beta™ for Livestock, as well as assist in securing potential licensing and distribution partners in those markets. Avivagen has engaged BioPharmaPotentials, a consulting firm that works with select inventors, entrepreneurs, investigators and investors to maximize the full potential for new and current chemical and biologic entities within the field of animal health. BioPharmaPotentials’ founder and CEO, Dr. Edward Robb, DVM, MS, DACVN, has held leadership research and development positions at Boehringer-Ingelheim Vetmedica, Pfizer Animal Health, Pharmacia and Upjohn Animal Health, Parnell, CEVA, Embrex and American Cyanamid. About Avivagen Avivagen Inc. is a public Corporation traded on the TSXV under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com. About OxC-beta™ Technology and OxC-beta™ Livestock Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about carotenoids, compounds that give certain fruits and vegetables their bright colors and is a non-antibiotic means of maintaining optimal health and growth. OxC-beta™ Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds.  OxC-beta™ Livestock is currently registered and available for sale in the Philippines, Taiwan and Thailand. Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics. Forward Looking Statements This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, ”helps”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions or opinions of management. Statements relating to Avivagen’s planned activities with its regulatory consulting firm, its plans to seek regulatory approval in additional jurisdictions and the potential effects of the receipt of any such approvals, are all forward-looking statements. Avivagen faces risks and uncertainties in connection with its business, including, but not limited to, risks relating to the following: Avivagen’s ability to continue as a going concern; whether the Corporation can expand its global regulatory advisor network in order to gain market approval of OxC-beta™; whether the Corporation can obtain market approval in additional geographies, if at all; whether it will be able to replace the antibiotics added to livestock feeds as growth promoters, whether it will confirm and expedite potential regulatory approvals of Avivagen’s OxC-beta™ for Livestock in major markets around the world, whether it will seek and be able to confirm the regulatory pathway for approvals in the U.S., Europe, South America and all other important markets, whether it will confirm, define and potentially expedite regulatory pathways for approval, whether any such approvals will be applied for or received in a timely manner or at all,  whether it will increase the market access of OxC-beta™ for Livestock, whether it will secure potential licensing and distribution partners in those markets and whether it can assure the full potential for the Corporation.   Avivagen may decide not to seek regulatory approval for its products in additional jurisdictions, regulatory approvals for Avivagen’s products may not be available in one or more additional jurisdictions in a timely or cost effective manner, if at all, and, if received, such approvals may not have the anticipated positive effects on the Corporation’s business and prospects. Readers should also refer to the risk factors in Avivagen’s annual information form and other securities law filings from time to time. Accordingly, readers should not place undue or even any reliance on forward-looking statements.  Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


News Article | May 12, 2017
Site: globenewswire.com

OTTAWA, Ontario, May 12, 2017 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV) (OTC Pink:CHEXF) (Avivagen or the Corporation), a Corporation with a proven and commercially-ready, patent-protected product intended to replace the antibiotics added to livestock feeds as growth promoters, announces the hiring of a regulatory consulting firm to work with the Corporation to analyze and seek regulatory approvals of Avivagen’s OxC-beta™ for Livestock in the United States. Avivagen has already secured approvals in several Asian markets and will be seeking to confirm the regulatory pathway for approvals in the U.S., Europe, South America and other important markets. Avivagen believes that obtaining  regulatory approval in additional jurisdictions could  increase the market access of OxC-beta™ for Livestock, as well as assist in securing potential licensing and distribution partners in those markets. Avivagen has engaged BioPharmaPotentials, a consulting firm that works with select inventors, entrepreneurs, investigators and investors to maximize the full potential for new and current chemical and biologic entities within the field of animal health. BioPharmaPotentials’ founder and CEO, Dr. Edward Robb, DVM, MS, DACVN, has held leadership research and development positions at Boehringer-Ingelheim Vetmedica, Pfizer Animal Health, Pharmacia and Upjohn Animal Health, Parnell, CEVA, Embrex and American Cyanamid. About Avivagen Avivagen Inc. is a public Corporation traded on the TSXV under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com. About OxC-beta™ Technology and OxC-beta™ Livestock Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about carotenoids, compounds that give certain fruits and vegetables their bright colors and is a non-antibiotic means of maintaining optimal health and growth. OxC-beta™ Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds.  OxC-beta™ Livestock is currently registered and available for sale in the Philippines, Taiwan and Thailand. Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics. Forward Looking Statements This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, ”helps”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions or opinions of management. Statements relating to Avivagen’s planned activities with its regulatory consulting firm, its plans to seek regulatory approval in additional jurisdictions and the potential effects of the receipt of any such approvals, are all forward-looking statements. Avivagen faces risks and uncertainties in connection with its business, including, but not limited to, risks relating to the following: Avivagen’s ability to continue as a going concern; whether the Corporation can expand its global regulatory advisor network in order to gain market approval of OxC-beta™; whether the Corporation can obtain market approval in additional geographies, if at all; whether it will be able to replace the antibiotics added to livestock feeds as growth promoters, whether it will confirm and expedite potential regulatory approvals of Avivagen’s OxC-beta™ for Livestock in major markets around the world, whether it will seek and be able to confirm the regulatory pathway for approvals in the U.S., Europe, South America and all other important markets, whether it will confirm, define and potentially expedite regulatory pathways for approval, whether any such approvals will be applied for or received in a timely manner or at all,  whether it will increase the market access of OxC-beta™ for Livestock, whether it will secure potential licensing and distribution partners in those markets and whether it can assure the full potential for the Corporation.   Avivagen may decide not to seek regulatory approval for its products in additional jurisdictions, regulatory approvals for Avivagen’s products may not be available in one or more additional jurisdictions in a timely or cost effective manner, if at all, and, if received, such approvals may not have the anticipated positive effects on the Corporation’s business and prospects. Readers should also refer to the risk factors in Avivagen’s annual information form and other securities law filings from time to time. Accordingly, readers should not place undue or even any reliance on forward-looking statements.  Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


News Article | May 11, 2017
Site: www.businesswire.com

CAMBRIDGE, Mass.--(BUSINESS WIRE)--BioAxone BioSciences, Inc., a clinical-stage biotechnology company focused on developing innovative drugs to restore neurological function, today welcomed Eric Floyd, Ph.D., and Darryl Patrick, DVM, Ph.D., to lead the company’s Investigational New Drug (IND) enabling team to support the planned IND filing for BA-1049, a new chemical entity in development to target cerebral cavernous malformation (CCM). Lisa McKerracher, Ph.D., CEO of BioAxone BioSciences noted, “I am excited to have Eric and Darryl on board. I look forward to leveraging their experience with IND enablement as we work to bring BA-1049 into clinical trials. Our work in CCM is a natural follow-on to our expertise in spinal cord injury where we are in Phase 2b/3 clinical trials in partnership with Vertex.” Eric Floyd has extensive experience working with the US Food and Drug Administration (FDA), and has led global regulatory affairs and quality assurance divisions within Novartis, Cephalon, Hospira and, most recently, Lundbeck. Darryl Patrick’s expertise includes early drug development efforts, and in particular those focused on novel therapeutic targets with unmet needs. Previously, he led exploratory and nonclinical development for Vertex overseeing toxicology and absorption. About BA-1049 BA-1049 is a first-in-class Rho kinase 2 (ROCK2) inhibitor targeting the protein kinase that causes cerebral cavernous malformation (CCM). BA-1049 normalizes ROCK2 signaling in brain endothelial cells thus restoring the blood-brain barrier function. About Cerebral Cavernous Malformation (CCM) Cerebral cavernous malformation (CCM) is a serious genetic disease which allows blood to leak into the brain. In patients with CCM, endothelial cells form single or multiple cystic brain lesions that leak and may cause seizure, hemorrhagic stroke and neurological deficits. Inherited cases of CCM are caused by loss of function in one of the 3 CCM genes (CCM1, CCM2 and CCM3) and the numbers of lesions rise with age, increasing risk of a hemorrhagic event. Sporadic cases result from mutations in the same genes. About BioAxone BioSciences BioAxone BioSciences is a clinical-stage biotechnology company developing innovative drugs to restore neurological function for patients with Spinal Cord Injuries (SCI) and vascular malformations in central nervous system with unmet medical needs. Led by a team of scientists renowned for their work on axon regeneration and neuronal signaling pathways, BioAxone has a pioneering SCI drug currently in a Phase 2b/3 clinical trial with Vertex, and is positioned to move other candidates into clinical trials. For more information, visit www.bioaxonebio.com


News Article | May 13, 2017
Site: www.prweb.com

With massive tornadoes hitting Texas the end of April, taking at least four lives, injuring dozens more and destroying countless homes, it couldn’t be more timely to recognize National Animal Disaster Preparedness Day. The awareness event serves as a call-to-action to prepare for not only tornadoes but also all types of emergencies, and the Texas Veterinary Medical Association (TVMA) urges pet owners to include pets in disaster preparation plans. One of the key components of developing a disaster preparation plan is establishing an evacuation strategy, which involves determining how to get your pets safely out of the house and off the property and finding a safe place to stay. Many disaster shelters do not accept pets, so find one that does ahead of time or secure an alternative safe haven for your pets. Consider making arrangements for boarding in case of home destruction. In addition to dogs and cats, it is crucial to plan ahead and make sure farm animals and livestock are also accounted for. It is important to assemble a survival kit for each of your pets. Just as humans need food, water and additional items such as medication, pets will need an ample supply of these things as well. In the kits, there should be at least three days worth of food and water, photos of pets for identification, proof of health care, emergency contact information and your veterinarian’s contact information. The American Veterinary Medical Association (AVMA) has species-specific guides and resources available to the public to ensure you have all possible necessities. Making sure your pet is properly identified is also imperative. If your pets happen to get lost during an evacuation or a disaster, you will have a much better chance of finding them if they are microchipped and tagged. It is also important to maintain an up-to-date contact information list with phone numbers for the veterinarian, fire department, police station, animal shelter and the nearest relative or friend who could shelter your pet. “We may not always be together at home with our family and pets when disaster strikes, so we have to be prepared to communicate with and relocate our family and pets,” said TVMA Immediate Past President Sam Miller, DVM, of Village Veterinary Clinic in Houston. “In the event you are away from home, it would be a good idea for a neighbor or family member to have access to your house so they can assist in your disaster response.” About the Texas Veterinary Medical Association Founded in 1903, the Texas Veterinary Medical Association is a professional association composed of more than 3,700 veterinarians committed to protecting public health, promoting high educational, ethical and moral standards within the veterinary profession and educating the public about animal health and its relationship to human health. For more information, call 512/452-4224 or visit http://www.tvma.org. ###


NEW YORK, May 12, 2017 - From May 15th to 17th the New York Academy of Sciences in partnership with the Myasthenia Gravis Foundation of America will host the 13th International Conference on Myasthenia Gravis and Related Disorders. The conference convenes every five years and is the preeminent gathering of basic scientists and clinical researchers to discuss, disseminate, and highlight the advances and challenges of therapies for myasthenia gravis (MG) and related autoimmune diseases. MG is a rare, acquired autoimmune syndrome that results in weakness and fatigue in the voluntary musculature of patients. Debilitating symptoms of this disease include vision impairment and loss, slurred speech, difficulty swallowing, choking, and loss of coordination, resulting in a diminished quality of life as well as decreased life expectancy for some sufferers of this syndrome. Linda L. Kusner, PhD, Associate Research Professor of Pharmacology & Physiology at George Washington University and Conference Organizing Committee Co-Chair, noted, "The 13th International Conference on Myasthenia Gravis and Related Disorders gathers a community of scientists and clinicians from around the world that work to better understand diseases of the neuromuscular junction and provide information on improved diagnostics and therapeutics. During the three-day conference, we work as a team dedicated to find the cure." The prevalence of MG in the United States is estimated as occurring in 20 per 100,000 people. While modern medical advances have helped decrease the symptoms of the disease, there has been an increase in reported cases, especially among the aging population. The number of diagnosed MG cases is expected to rise as the aging population increases and screening techniques improve. From a public health perspective it is clear that an increased understanding of the etiology underlying MG is critical for enhancing diagnosis and treatment of this disease. "Linda and I were so fortunate to work with a program advisory committee, made up of top-shelf scientists and clinicians from around the world, to come up with a program we think nicely covers so many important aspects of this disease," said Ted M. Burns, MD, Professor of Neurology at the University of Virginia and Conference Organizing Committee Co-Chair. The three-day conference will focus on the most critical topics for translating basic laboratory discoveries into real-world treatments for MG. Basic scientists and clinical researchers from academic institutions, treatment centers, pharmaceutical companies, government agencies, and non-profit organizations will review current MG treatment options, ongoing clinical trials, and clinical limitations, while identifying current gaps in knowledge and future directions that could lead to potential breakthroughs. Speakers will include a keynote presentation from Vijay Kuchroo, DVM, PhD, from Harvard Institutes of Medicine on "T cell Function in Autoimmunity." The conference will conclude with a panel discussion with an international group of experts, to discuss "Comparing and Contrasting Treatment Strategies around the World." "We at the Myasthenia Gravis Foundation of America are proud to convene this meeting with most of the world's top scientists and clinicians in the field of myasthenia gravis in attendance," said Nancy Law, Chief Executive Officer of the Myasthenia Gravis Foundation of America. "We thank the organizing committee, led by Drs. Linda Kusner and Ted Burns, and the New York Academy of Sciences for their partnership in making this the most prestigious conference on MG and related disorders in the world." If you are interested in attending this event in person or viewing the webinar please visit the registration page for additional information. The New York Academy of Sciences is an independent, not-for-profit organization that since 1817 has been driving innovative solutions to society's challenges by advancing scientific research, education, and policy. With more than 20,000 Members in 100 countries, the Academy is creating a global community of science for the benefit of humanity. Please visit us online at http://www. and follow us on Twitter at @NYASciences. MGFA is the only national volunteer health agency in the United States dedicated solely to the fight against MG. MGFA is committed to finding a cure for myasthenia gravis and closely related disorders, improving treatment options, and providing information and support to people with MG through research, education, community programs, and advocacy. Visit our website at http://www. , email us at MGFA@mysathenia.org, or call 1-800-541-5454.


News Article | May 10, 2017
Site: globenewswire.com

New York, 2017-05-10 08:40 CEST (GLOBE NEWSWIRE) -- The Board of Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, has made a decision to move all of Oasmia’s veterinary assets, including Paccal Vet and Doxophos Vet, to a wholly owned subsidiary in the United States. The transfer is made to provide a solid financial foundation for further development and commercialization of the veterinary business on the US market. Based on an independent valuation by one of the big four accounting firms, the fair market value of the registered intellectual property relating to Oasmia’s animal oncology products, Paccal Vet and Doxophos Vet, is assessed in the range of USD 75 - 80 million. This independent valuation in a potential transaction could differ from the indicated range. The Company has appointed New York based advisors to evaluate potential financial and strategic alternatives for the veterinary business, including  private placement, public offering of the common stock in the U.S. subsidiary and strategic collaborations within the veterinary field. These activities will commence at once. According to the American Pet Products Association, it is estimated that 78 million dogs are owned in the U.S. As these numbers continue to rise, so too does the animal health market, which is current estimated at USD 24 billion. A recent report from the Houston Technology Center states that, in the U.S. alone, an estimated 13 to 25 million dogs are living with cancer. Unfortunately, less than 20% survive longer than two years due to unsuccessful treatments, as well as the fact that there are only approximately 375 specialized veterinary oncologists in the country. As previously stated, Oasmia has temporarily withdrawn its FDA approval for Paccal Vet in order to lower the dosage to reduce side effects and improve comfort for companion animals, before resubmitting for review. This was a strategic move, as in the past, the product had only been available for use by specialized veterinary oncologists. Upon resubmission and what Oasmia considers likely approval, Paccal Vet would be available for use to the much broader approximately 42,000 general veterinary practitioners in the U.S. Further, Doxophos Vet, a patented formulation of doxorubicin and Oasmia’s patented XR17 technology that has received Minor Use Minor Species (MUMS) designation from the FDA, is approaching the conclusion of its clinical study. Doxophos Vet represents tremendous market upside in one of the leading cancer indications for dogs, lymphoma, which impacts approximately 200,000 dogs each year in the US alone. “The transfer of our veterinary assets to a separate U.S. company accomplishes strategic objectives, increased focus on our veterinary business with American partners that we expect to thrive in a high-growth market,” said Henrik Rönnberg, Professor, DVM, DiplECVIM-CA (oncology) and Chief Medical Officer at Oasmia Pharmaceutical. “The market trajectory for animal oncology products is staggering, with few products available for animal companions, and the families who care about them so much. We believe this step provides the division with the infrastructure it requires, opening up for financing of future sales- and marketing activities so that we on a broad scale can capture the market.” Oasmia Pharmaceutical AB develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Capital Markets (OASM.US), Frankfurt Stock Exchange (OMAX.GR, ISIN SE0000722365) and NASDAQ Stockholm (OASM.ST).


News Article | May 10, 2017
Site: globenewswire.com

New York, 2017-05-10 08:40 CEST (GLOBE NEWSWIRE) -- The Board of Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, has made a decision to move all of Oasmia’s veterinary assets, including Paccal Vet and Doxophos Vet, to a wholly owned subsidiary in the United States. The transfer is made to provide a solid financial foundation for further development and commercialization of the veterinary business on the US market. Based on an independent valuation by one of the big four accounting firms, the fair market value of the registered intellectual property relating to Oasmia’s animal oncology products, Paccal Vet and Doxophos Vet, is assessed in the range of USD 75 - 80 million. This independent valuation in a potential transaction could differ from the indicated range. The Company has appointed New York based advisors to evaluate potential financial and strategic alternatives for the veterinary business, including  private placement, public offering of the common stock in the U.S. subsidiary and strategic collaborations within the veterinary field. These activities will commence at once. According to the American Pet Products Association, it is estimated that 78 million dogs are owned in the U.S. As these numbers continue to rise, so too does the animal health market, which is current estimated at USD 24 billion. A recent report from the Houston Technology Center states that, in the U.S. alone, an estimated 13 to 25 million dogs are living with cancer. Unfortunately, less than 20% survive longer than two years due to unsuccessful treatments, as well as the fact that there are only approximately 375 specialized veterinary oncologists in the country. As previously stated, Oasmia has temporarily withdrawn its FDA approval for Paccal Vet in order to lower the dosage to reduce side effects and improve comfort for companion animals, before resubmitting for review. This was a strategic move, as in the past, the product had only been available for use by specialized veterinary oncologists. Upon resubmission and what Oasmia considers likely approval, Paccal Vet would be available for use to the much broader approximately 42,000 general veterinary practitioners in the U.S. Further, Doxophos Vet, a patented formulation of doxorubicin and Oasmia’s patented XR17 technology that has received Minor Use Minor Species (MUMS) designation from the FDA, is approaching the conclusion of its clinical study. Doxophos Vet represents tremendous market upside in one of the leading cancer indications for dogs, lymphoma, which impacts approximately 200,000 dogs each year in the US alone. “The transfer of our veterinary assets to a separate U.S. company accomplishes strategic objectives, increased focus on our veterinary business with American partners that we expect to thrive in a high-growth market,” said Henrik Rönnberg, Professor, DVM, DiplECVIM-CA (oncology) and Chief Medical Officer at Oasmia Pharmaceutical. “The market trajectory for animal oncology products is staggering, with few products available for animal companions, and the families who care about them so much. We believe this step provides the division with the infrastructure it requires, opening up for financing of future sales- and marketing activities so that we on a broad scale can capture the market.” Oasmia Pharmaceutical AB develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Capital Markets (OASM.US), Frankfurt Stock Exchange (OMAX.GR, ISIN SE0000722365) and NASDAQ Stockholm (OASM.ST).


News Article | May 12, 2017
Site: globenewswire.com

OTTAWA, Ontario, May 12, 2017 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV) (OTC Pink:CHEXF) (Avivagen or the Corporation), a Corporation with a proven and commercially-ready, patent-protected product intended to replace the antibiotics added to livestock feeds as growth promoters, announces the hiring of a regulatory consulting firm to work with the Corporation to analyze and seek regulatory approvals of Avivagen’s OxC-beta™ for Livestock in the United States. Avivagen has already secured approvals in several Asian markets and will be seeking to confirm the regulatory pathway for approvals in the U.S., Europe, South America and other important markets. Avivagen believes that obtaining  regulatory approval in additional jurisdictions could  increase the market access of OxC-beta™ for Livestock, as well as assist in securing potential licensing and distribution partners in those markets. Avivagen has engaged BioPharmaPotentials, a consulting firm that works with select inventors, entrepreneurs, investigators and investors to maximize the full potential for new and current chemical and biologic entities within the field of animal health. BioPharmaPotentials’ founder and CEO, Dr. Edward Robb, DVM, MS, DACVN, has held leadership research and development positions at Boehringer-Ingelheim Vetmedica, Pfizer Animal Health, Pharmacia and Upjohn Animal Health, Parnell, CEVA, Embrex and American Cyanamid. About Avivagen Avivagen Inc. is a public Corporation traded on the TSXV under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com. About OxC-beta™ Technology and OxC-beta™ Livestock Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about carotenoids, compounds that give certain fruits and vegetables their bright colors and is a non-antibiotic means of maintaining optimal health and growth. OxC-beta™ Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds.  OxC-beta™ Livestock is currently registered and available for sale in the Philippines, Taiwan and Thailand. Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics. Forward Looking Statements This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, ”helps”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions or opinions of management. Statements relating to Avivagen’s planned activities with its regulatory consulting firm, its plans to seek regulatory approval in additional jurisdictions and the potential effects of the receipt of any such approvals, are all forward-looking statements. Avivagen faces risks and uncertainties in connection with its business, including, but not limited to, risks relating to the following: Avivagen’s ability to continue as a going concern; whether the Corporation can expand its global regulatory advisor network in order to gain market approval of OxC-beta™; whether the Corporation can obtain market approval in additional geographies, if at all; whether it will be able to replace the antibiotics added to livestock feeds as growth promoters, whether it will confirm and expedite potential regulatory approvals of Avivagen’s OxC-beta™ for Livestock in major markets around the world, whether it will seek and be able to confirm the regulatory pathway for approvals in the U.S., Europe, South America and all other important markets, whether it will confirm, define and potentially expedite regulatory pathways for approval, whether any such approvals will be applied for or received in a timely manner or at all,  whether it will increase the market access of OxC-beta™ for Livestock, whether it will secure potential licensing and distribution partners in those markets and whether it can assure the full potential for the Corporation.   Avivagen may decide not to seek regulatory approval for its products in additional jurisdictions, regulatory approvals for Avivagen’s products may not be available in one or more additional jurisdictions in a timely or cost effective manner, if at all, and, if received, such approvals may not have the anticipated positive effects on the Corporation’s business and prospects. Readers should also refer to the risk factors in Avivagen’s annual information form and other securities law filings from time to time. Accordingly, readers should not place undue or even any reliance on forward-looking statements.  Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


News Article | May 12, 2017
Site: globenewswire.com

OTTAWA, Ontario, May 12, 2017 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV) (OTC Pink:CHEXF) (Avivagen or the Corporation), a Corporation with a proven and commercially-ready, patent-protected product intended to replace the antibiotics added to livestock feeds as growth promoters, announces the hiring of a regulatory consulting firm to work with the Corporation to analyze and seek regulatory approvals of Avivagen’s OxC-beta™ for Livestock in the United States. Avivagen has already secured approvals in several Asian markets and will be seeking to confirm the regulatory pathway for approvals in the U.S., Europe, South America and other important markets. Avivagen believes that obtaining  regulatory approval in additional jurisdictions could  increase the market access of OxC-beta™ for Livestock, as well as assist in securing potential licensing and distribution partners in those markets. Avivagen has engaged BioPharmaPotentials, a consulting firm that works with select inventors, entrepreneurs, investigators and investors to maximize the full potential for new and current chemical and biologic entities within the field of animal health. BioPharmaPotentials’ founder and CEO, Dr. Edward Robb, DVM, MS, DACVN, has held leadership research and development positions at Boehringer-Ingelheim Vetmedica, Pfizer Animal Health, Pharmacia and Upjohn Animal Health, Parnell, CEVA, Embrex and American Cyanamid. About Avivagen Avivagen Inc. is a public Corporation traded on the TSXV under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com. About OxC-beta™ Technology and OxC-beta™ Livestock Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about carotenoids, compounds that give certain fruits and vegetables their bright colors and is a non-antibiotic means of maintaining optimal health and growth. OxC-beta™ Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds.  OxC-beta™ Livestock is currently registered and available for sale in the Philippines, Taiwan and Thailand. Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics. Forward Looking Statements This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, ”helps”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions or opinions of management. Statements relating to Avivagen’s planned activities with its regulatory consulting firm, its plans to seek regulatory approval in additional jurisdictions and the potential effects of the receipt of any such approvals, are all forward-looking statements. Avivagen faces risks and uncertainties in connection with its business, including, but not limited to, risks relating to the following: Avivagen’s ability to continue as a going concern; whether the Corporation can expand its global regulatory advisor network in order to gain market approval of OxC-beta™; whether the Corporation can obtain market approval in additional geographies, if at all; whether it will be able to replace the antibiotics added to livestock feeds as growth promoters, whether it will confirm and expedite potential regulatory approvals of Avivagen’s OxC-beta™ for Livestock in major markets around the world, whether it will seek and be able to confirm the regulatory pathway for approvals in the U.S., Europe, South America and all other important markets, whether it will confirm, define and potentially expedite regulatory pathways for approval, whether any such approvals will be applied for or received in a timely manner or at all,  whether it will increase the market access of OxC-beta™ for Livestock, whether it will secure potential licensing and distribution partners in those markets and whether it can assure the full potential for the Corporation.   Avivagen may decide not to seek regulatory approval for its products in additional jurisdictions, regulatory approvals for Avivagen’s products may not be available in one or more additional jurisdictions in a timely or cost effective manner, if at all, and, if received, such approvals may not have the anticipated positive effects on the Corporation’s business and prospects. Readers should also refer to the risk factors in Avivagen’s annual information form and other securities law filings from time to time. Accordingly, readers should not place undue or even any reliance on forward-looking statements.  Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


News Article | May 12, 2017
Site: globenewswire.com

OTTAWA, Ontario, May 12, 2017 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV) (OTC Pink:CHEXF) (Avivagen or the Corporation), a Corporation with a proven and commercially-ready, patent-protected product intended to replace the antibiotics added to livestock feeds as growth promoters, announces the hiring of a regulatory consulting firm to work with the Corporation to analyze and seek regulatory approvals of Avivagen’s OxC-beta™ for Livestock in the United States. Avivagen has already secured approvals in several Asian markets and will be seeking to confirm the regulatory pathway for approvals in the U.S., Europe, South America and other important markets. Avivagen believes that obtaining  regulatory approval in additional jurisdictions could  increase the market access of OxC-beta™ for Livestock, as well as assist in securing potential licensing and distribution partners in those markets. Avivagen has engaged BioPharmaPotentials, a consulting firm that works with select inventors, entrepreneurs, investigators and investors to maximize the full potential for new and current chemical and biologic entities within the field of animal health. BioPharmaPotentials’ founder and CEO, Dr. Edward Robb, DVM, MS, DACVN, has held leadership research and development positions at Boehringer-Ingelheim Vetmedica, Pfizer Animal Health, Pharmacia and Upjohn Animal Health, Parnell, CEVA, Embrex and American Cyanamid. About Avivagen Avivagen Inc. is a public Corporation traded on the TSXV under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com. About OxC-beta™ Technology and OxC-beta™ Livestock Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about carotenoids, compounds that give certain fruits and vegetables their bright colors and is a non-antibiotic means of maintaining optimal health and growth. OxC-beta™ Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds.  OxC-beta™ Livestock is currently registered and available for sale in the Philippines, Taiwan and Thailand. Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics. Forward Looking Statements This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, ”helps”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions or opinions of management. Statements relating to Avivagen’s planned activities with its regulatory consulting firm, its plans to seek regulatory approval in additional jurisdictions and the potential effects of the receipt of any such approvals, are all forward-looking statements. Avivagen faces risks and uncertainties in connection with its business, including, but not limited to, risks relating to the following: Avivagen’s ability to continue as a going concern; whether the Corporation can expand its global regulatory advisor network in order to gain market approval of OxC-beta™; whether the Corporation can obtain market approval in additional geographies, if at all; whether it will be able to replace the antibiotics added to livestock feeds as growth promoters, whether it will confirm and expedite potential regulatory approvals of Avivagen’s OxC-beta™ for Livestock in major markets around the world, whether it will seek and be able to confirm the regulatory pathway for approvals in the U.S., Europe, South America and all other important markets, whether it will confirm, define and potentially expedite regulatory pathways for approval, whether any such approvals will be applied for or received in a timely manner or at all,  whether it will increase the market access of OxC-beta™ for Livestock, whether it will secure potential licensing and distribution partners in those markets and whether it can assure the full potential for the Corporation.   Avivagen may decide not to seek regulatory approval for its products in additional jurisdictions, regulatory approvals for Avivagen’s products may not be available in one or more additional jurisdictions in a timely or cost effective manner, if at all, and, if received, such approvals may not have the anticipated positive effects on the Corporation’s business and prospects. Readers should also refer to the risk factors in Avivagen’s annual information form and other securities law filings from time to time. Accordingly, readers should not place undue or even any reliance on forward-looking statements.  Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Loading DVM collaborators
Loading DVM collaborators